DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
TMO logo

Thermo Fisher Scientific Inc. Stock Price

NYSE:TMO Community·US$224.0b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 265 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TMO Share Price Performance

US$603.18
111.77 (22.74%)
​
US$631.42
Fair Value
US$603.18
111.77 (22.74%)
4.5% undervalued intrinsic discount
US$631.42
Fair Value
Price US$603.18
AnalystConsensusTarget US$631.42
Unike US$540.27
AnalystLowTarget US$535.02
Thu, 20 Aug 26
Fair ValueUS$631.42
Share Pricen/a

TMO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$631.42 4.5% undervalued intrinsic discount

Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum

0users have liked this narrative
0users have commented on this narrative
91users have followed this narrative
UN
Unike's
Fair Value
·
Fair Value US$540.27 11.6% overvalued intrinsic discount

The demand for personalized medicine will keep Thermo Fisher Scientific thriving

1users have liked this narrative
0users have commented on this narrative
33users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$535.02 12.7% overvalued intrinsic discount

US China Tensions And Trade Restrictions Will Impair Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
TMO logo
Thermo Fisher Scientific
11.6% overvalued intrinsic discount

The demand for personalized medicine will keep Thermo Fisher Scientific thriving

View narrative
UN
Unike
Published 10 Mar 2025
Read Narrative
TMO logo
Thermo Fisher Scientific
4.5% undervalued intrinsic discount

Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Aug
Read Narrative
TMO logo
Thermo Fisher Scientific
17.5% undervalued intrinsic discount

Aging Populations And Gene Therapies Will Drive Precision Medicine

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
TMO logo
Thermo Fisher Scientific
12.7% overvalued intrinsic discount

US China Tensions And Trade Restrictions Will Impair Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 6 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

UN
TMO logo

The demand for personalized medicine will keep Thermo Fisher Scientific thriving

Fair Value: US$540.27 11.6% overvalued intrinsic discount
33 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
TMO logo

TMO: Protein Design And Personalized Vaccines Will Drive Future Upside

Fair Value: US$731.02 17.5% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
TMO logo

TMO: AI Tools And Biopharma Demand Offset End Market Uncertainty

Fair Value: US$631.42 4.5% undervalued intrinsic discount
91 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with mediocre balance sheet.

1 Risk
3 Rewards
View Full Analysis

Thermo Fisher Scientific Inc. Key Details

US$46.3b

Revenue

US$27.3b

Cost of Revenue

US$19.0b

Gross Profit

US$12.0b

Other Expenses

US$7.0b

Earnings

Last Reported Earnings
Jun 27, 2026
Next Reporting Earnings
n/a
18.84
40.99%
15.04%
80.1%
View Full Analysis

About TMO

Founded
1956
Employees
125000
CEO
Marc Casper
WebsiteView website
www.thermofisher.com

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Recent TMO News & Updates

User avatar
Narrative Update • Sep 03

TMO: Protein Design And Personalized Vaccines Will Drive Future Upside

Analysts have lifted their Thermo Fisher Scientific fair value estimate from $704.62 to $731.02. This reflects updated views on slightly higher discount rates, modestly softer revenue growth assumptions, firmer profit margins, and a marginally higher future P/E multiple informed by a series of recent price target increases and supportive sector commentary.

Recent updates

No updates

Thermo Fisher Scientific Inc. Competitors

LLY logo

Eli Lilly

Symbol: NYSE:LLY
Market cap: US$1.0t
JNJ logo

Johnson & Johnson

Symbol: NYSE:JNJ
Market cap: US$643.6b
ABBV logo

AbbVie

Symbol: NYSE:ABBV
Market cap: US$443.4b
MRK logo

Merck

Symbol: NYSE:MRK
Market cap: US$364.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide